Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 26 March 2020
Accepted: 19 May 2020
First Online: 6 June 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The authors (JAL and FS) have intellectual property on the use of the neuregulin antagonist fusion protein to treat neurodegenerative diseases.
